Overweight and obesity is an increasing health problem, not only for industrialised countries but also for most other parts of the world. This epidemic appears to be affecting all ages, including childhood ([WHO, 2000](#bib30){ref-type="other"}). Prospective studies have observed an association between overweight and overall mortality ([Lew and Garfinkel, 1979](#bib14){ref-type="other"}; [Manson *et al*, 1995](#bib15){ref-type="other"}; [Calle *et al*, 1999](#bib5){ref-type="other"}), and several adverse health consequences of elevated body weight are well established, including type II diabetes, hypertension and coronary heart disease ([Must *et al*, 1999](#bib18){ref-type="other"}). Obesity has also been associated with cancer incidence and mortality, and positive associations between obesity and risks of specific cancers, including endometrial and kidney cancer, are widely accepted ([Calle and Kaaks, 2004](#bib2){ref-type="other"}). Inconsistent evidence of associations between other cancers and body weight may be due in part to small sample sizes and misclassification of body weight in retrospective studies. The relation between body mass index (BMI) and incidence of different cancers as ascertained by population-based cancer registries has been investigated by few studies ([Moller *et al*, 1994](#bib16){ref-type="other"}; [Wolk *et al*, 2001](#bib31){ref-type="other"}). We conducted a prospective investigation of the association between overweight and the incidence of cancer (overall and specific types) using data from the Vorarlberg cancer registry and a population-based cohort of more than 145 000 Austrian men and women followed for an average of nearly 10 years.

MATERIALS AND METHODS
=====================

Study population
----------------

The Vorarlberg Health Monitoring and Promotion Program (VHM&PP) is carried out in Vorarlberg, the westernmost province of Austria. It is performed routinely by the Agency of Social and Preventive Medicine and covers all adults of the whole province. The screening examination takes place in the practice of local physicians; it includes a physical examination, a blood test and a consultation with a doctor. Enrolment is voluntary and costs are covered by the participant\'s (compulsory) health insurance. More than two-thirds of the adult population of the province (between the age of 35 and 54 years) participated and underwent at least one examination since the beginning of the programme in 1985 ([Ulmer *et al*, 2004](#bib29){ref-type="other"}). The VHM&PP has been described in detail previously ([Ulmer *et al*, 2003](#bib28){ref-type="other"}).

Between 1985 and 2001, 167 371 adult Vorarlberg residents were enrolled in the VHM&PP Study Cohort after signing an informed consent to store and process personal data (height, weight, smoking and other factors). The current analysis was restricted to participants with complete data on height, weight and occupational group at enrolment. As in a previous study ([Calle *et al*, 2003](#bib4){ref-type="other"}), participants with a baseline BMI (kg m^−2^) below normal (BMI\<18.5 kg m^−2^, *n*=5053) were excluded. In order to avoid an influence of cancer growth on body weight, participants were further excluded if they had been diagnosed with a malignant cancer prior to enrolment, or within 1 year following enrolment (*n*=1831). Therefore, the first year of follow-up time was not considered in the analysis and participants with a follow-up period of less than 1 year (*n*=5528) were excluded. To evaluate the sensitivity of our analyses to this 1-year exclusion, we also repeated the analyses with a 3-year exclusion. The final study cohort consisted of 67 447 men and 78 484 women, with mean age at study entry of 41.8 years for men and 42.5 years for women ([Table 1](#tbl1){ref-type="table"}). The average time of follow-up was nearly 10 years, with a total of 1.45 million person-years. By the end of the total observation period of 17 years, 6241 incident cancers (other than nonmelanoma skin cancer) had been diagnosed ([Table 1](#tbl1){ref-type="table"}).

Body mass index
---------------

Baseline height and weight were recorded by medical staff at enrolment during the VHM&PP physical examination. BMI was classified according to World Health Organisation guidelines as normal (18.50--24.99 kg m^−2^), overweight (25.00--29.99 kg m^−2^), obese class I (30.00--34.99 kg m^−2^), and obese class II and III (⩾35.00 kg m^−2^) (2000). Normal BMI was the reference category for all analyses, and obesity categories were combined when necessary to ensure a minimum of five cancer outcomes in each exposure group.

Covariates
----------

Associations were adjusted for smoking by including variables for current smoking and former smoking in the model, with the reference group being never smokers. Persons with missing smoking values were classified as never smokers because baseline questionnaire data did not differentiate between never-smokers and participants with missing values. However, smoking information from follow-up visits was available to validate the baseline smoking status of more than 70% of study participants. Occupational group (blue collar, white collar or self-employed) was determined by the insurance number of participants and was included in the models as a surrogate measure of socioeconomic status. Participants who were retired at baseline were classified according to their former occupation, and housewives according to their husband\'s occupation.

End points
----------

Between 1985 and 2002, incident invasive cancers were identified by the Vorarlberg cancer registry, which is accepted for publication by the International Agency for Research on Cancer (IARC) since 1993 ([Parkin *et al*, 2003](#bib22){ref-type="other"}). The proportion of cancers discovered by death certificate only (DCO) in the Vorarlberg registry for cases diagnosed between 1993 and 1997 was 7% for men and 9% for women ([Oberaigner *et al*, 2003](#bib20){ref-type="other"}), and for cases diagnosed between 1998 and 2002 about 5% in both sexes (W Oberaigner, personal communication, Cancer Registry of Tyrol). Nearly all cancers were histologically verified and coded according to the ninth revision of the *International Classification of Diseases* (ICD-9). Cohort data were linked with the Vorarlberg Death Index to identify deaths among cohort members to calculate person-years at risk.

Statistical analysis
--------------------

We used Cox proportional-hazards models to compute hazard rate ratios (HR) and 95% confidence intervals (95% CI) for overweight and obesity relative to normal BMI, adjusted for smoking and occupational group at baseline. The models included age (in single years) in the strata statement. In tests of linear trend by BMI, the median value for BMI within each interval was entered in a regression model, and the significance of the term tested by the Wald\'s *χ*^2^ test. All calculations were carried out with SAS version 8.2 software.

All analyses were performed separately for men and women. Analyses on specific cancers were restricted to those types of cancer with at least 50 cases in men or women.

RESULTS
=======

The study cohort consisted of 67 447 men and 78 484 women ([Table 1](#tbl1){ref-type="table"}). In men, positive linear trends in cancer incidence with increasing BMI were observed for colon and pancreatic cancer ([Table 2](#tbl2){ref-type="table"}). In comparison to men with normal weight, the hazard ratios for colon cancer were 1.56 (95% CI: 1.06, 2.30) for men with BMI 30.0--34.99 kg m^−2^, and 2.48 (1.15, 5.39) for BMI 35.0 kg m^−2^ or more. The hazard ratios for men with BMI of at least 30.0 kg m^−2^ were for rectal cancer 1.66 (1.00, 2.73) and for pancreatic cancer 2.34 (1.17, 4.66). Nonsignificant positive associations were found for kidney and liver cancers.

In women, there was a weak positive association between BMI and all cancers ([Table 3](#tbl3){ref-type="table"}). Endometrial (uterine corpus) cancer was strongly associated with obesity class I (hazard ratio 2.13 (1.38, 3.27)) and obesity class II and III (hazard ratio 3.93 (2.35, 6.56)) in comparison to normal weight. Furthermore, a positive association was found between obesity and the incidence of non-Hodgkin\'s lymphomas (NHL) (hazard ratio 2.86 (1.49, 5.49), with a BMI of at least 30.0 kg m^−2^). Kidney cancer was associated with overweight, though not statistically significant. In contrast to men, BMI was not associated with colon or rectal cancer in women.

There was little evidence of an association between breast cancer and BMI overall. However, breast cancer diagnosed in women aged 65 years or older was positively associated with BMI (hazard ratios 1.48 (1.12, 1.95) for obesity class I and 1.29 (0.79, 2.11) for obesity class II and III; *P* for trend 0.02).

All associations that were statistically significant after exclusion of the first year following entry into the study remained unchanged in terms of statistical significance when reanalysed excluding the first 3 years.

DISCUSSION
==========

The major strengths of our study are the prospective design, the large number of subjects, the coverage of incident cases and the length of follow-up. The population of Vorarlberg is culturally and ethnically rather homogenous, with more than 90% of Austrian origin ([Ulmer *et al*, 2003](#bib28){ref-type="other"}). Body mass index was based on height and weight measured at initial physical examination. Incident cancers were ascertained by the population-based cancer registry and nearly all histologically confirmed; the likelihood of exposure and outcome misclassification was therefore low.

The limitations of our study include that, despite the overall size of the cohort, some cancers of interest (for example, oesophageal adenocarcinoma or gallbladder cancer) could not be evaluated due to small numbers of cases. In addition, the prevalence of obesity in our cohort was relatively low. Consequently the power to examine extreme levels of obesity, particularly in association with less common cancers, was limited. The high proportion of never-smoking patients with lung cancer (31%) suggests that there was some misclassification of smoking status, although this would probably attenuate the relation between BMI and most cancers, given the inverse association between smoking and body weight. We used occupational group as a rough surrogate for socioeconomic status, but were unable to account for such potentially confounding factors as alcohol consumption or physical activity.

Our finding of an association between BMI and both colon and rectum cancers in men supports earlier observations ([Lew and Garfinkel, 1979](#bib14){ref-type="other"}; [Giovannucci *et al*, 1995](#bib10){ref-type="other"}; [Pan *et al*, 2004](#bib21){ref-type="other"}; [Samanic *et al*, 2004](#bib24){ref-type="other"}) and may be due to the growth-promoting effects of insulin and insulin-like growth factor (IGF-1), both increased in obesity ([Calle and Kaaks, 2004](#bib2){ref-type="other"}). Our failure to find an association between BMI and colon cancer in women also agrees with other studies ([Phillips and Snowdon, 1985](#bib23){ref-type="other"}; [Shimizu *et al*, 2003](#bib25){ref-type="other"}), and may be related to the protective effects of elevated oestrogen levels in overweight postmenopausal women, as found by studies of exogenous hormone therapy in such women ([Calle *et al*, 1995](#bib3){ref-type="other"}; [Newcomb and Storer, 1995](#bib19){ref-type="other"}).

We observed a positive association between pancreatic cancer and overweight or obesity in men, and to a lesser extent in women. Other studies have been inconsistent in this connection ([Berrington *et al*, 2003](#bib1){ref-type="other"}). As with colon cancer, relations between pancreatic cancer and BMI have been attributed to the growth-promoting effects of elevated insulin and IGFs secondary to obesity ([Takeda and Escribano, 1991](#bib27){ref-type="other"}), although the carcinogenic effects of insulin have also been proposed to explain positive associations with abnormal glucose metabolism ([Gapstur *et al*, 2000](#bib9){ref-type="other"}) or diabetes mellitus ([Everhart and Wright, 1995](#bib8){ref-type="other"}).

In line with previous reports ([Yuan *et al*, 1998](#bib32){ref-type="other"}; [Chow *et al*, 2000](#bib7){ref-type="other"}), we observed a positive relation between BMI and incidence of kidney cancer in men, which, however, did not reach statistical significance. In women, our findings showed a positive association between kidney cancer and overweight, but not obesity. Our finding of a positive association between BMI and breast cancer only among women at the age of 65 years or older is consistent with previous reports ([Hunter and Willett, 1993](#bib12){ref-type="other"}).

A relation between endometrial cancer (cancer of the uterine corpus) and overweight is widely accepted ([Calle and Kaaks, 2004](#bib2){ref-type="other"}), and it was found that this in very obese women (BMI⩾35 kg m^−2^) were more likely to be diagnosed with endometrial cancer than women with normal BMI at baseline (HR 3.93, 95% CI: 2.35, 6.56). A crucial pathway seems to be oestrogens that are not counterbalanced by progesterone (the 'unopposed oestrogen\' hypothesis) ([Kaaks *et al*, 2002](#bib13){ref-type="other"}). Anovulatory cycles in obese premenopausal women may contribute to a deficiency of progesterone, which normally opposes the mitogenic effect of oestrogen on the endometrial mucosa.

We also observed a strong positive association between BMI and NHL among women, but not men. Previous prospective studies of overweight and NHL have been inconsistent ([Moller *et al*, 1994](#bib16){ref-type="other"}; [Wolk *et al*, 2001](#bib31){ref-type="other"}; [Cerhan *et al*, 2002](#bib6){ref-type="other"}; [Calle *et al*, 2003](#bib4){ref-type="other"}; [Samanic *et al*, 2004](#bib24){ref-type="other"}), though several case--control studies have reported an association between overweight and NHL in both sexes ([Holly *et al*, 1999](#bib11){ref-type="other"}; [Pan *et al*, 2004](#bib21){ref-type="other"}; [Skibola *et al*, 2004](#bib26){ref-type="other"}). The incidence of NHL has increased in many parts of the world ([Muller *et al*, 2005](#bib17){ref-type="other"}) and obesity might be a contributing factor.

As previously reported ([Calle and Kaaks, 2004](#bib2){ref-type="other"}), liver cancer showed a (non-significant) association with BMI in men with point estimates clearly above one, but based on only 57 cases; there were too few cases of liver cancer for a separate analysis in women.

Many studies have examined relations between overweight and single cancer outcomes. Few prospective studies examined the influence of overweight on a range of specific cancers both in men and women ([Lew and Garfinkel, 1979](#bib14){ref-type="other"}; [Moller *et al*, 1994](#bib16){ref-type="other"}; [Wolk *et al*, 2001](#bib31){ref-type="other"}; [Calle *et al*, 2003](#bib4){ref-type="other"}). Our study of a large Austrian cohort provides additional support from another population for associations between BMI and the incidence of colon, rectal and pancreatic cancer, and to a lesser extent of kidney and liver cancer in men, and with endometrial cancer, postmenopausal breast cancer and NHL in women.

We thank all physicians participating in the Vorarlberg Health Monitoring and Promotion Program (VHM&PP) for conducting the examinations and providing the data. The VHM&PP is supported by the State of Vorarlberg, Austria.

###### 

Characteristics of the VHM&PP study cohort

                                              **Men**        **Women**        **All**
  --------------------------------------- --------------- --------------- ---------------
  Eligible VHM&PP participants (*N*)^a^       67 447          78 484          145 931
                                                                                  
  *Age at entry (years)*                                                  
   Mean (s.d.^b^)                          41.78 (14.47)   42.48 (15.66)   42.16 (15.12)
   Range                                   18.66--93.03    19.00--94.13    18.66--94.13
                                                                                  
  *Years of follow-up*                                                    
   Mean (s.d.^b^)                           9.63 (4.63)    10.18 (4.56)     9.93 (4.60)
   Range                                    0.00--16.89     0.00--16.84     0.00--16.89
   Total person-years at risk                 649 358         799 122        1 448 480
                                                                                  
  *BMI*^c^ (%)                                                            
   Normal: 18.5--24.9 kg m^−2^                 50.47           62.86           57.13
   Overweight: 25--29.9 kg m^−2^               40.05           25.60           32.28
   Obese I: 30--34.9 kg m^−2^                  8.23            8.55            8.40
   Obese II and III: ⩾35 kg m^−2^              1.25            2.99            2.19
                                                                                  
  *Smoking* (%)                                                           
   Current smoker                              29.99           20.78           25.03
   Former smoker                               13.27           4.99            8.79
                                                                                  
  *Occupational group*^d^ (%)                                             
   Blue collar                                 37.29           38.09           37.72
   White collar                                51.99           54.08           53.12
   Self-employed                               10.72           7.82            9.16
                                                                                  
  Number of cancers                            3337            2904            6241
                                                                                  
  *Age at cancer diagnosis (years)*                                       
   Mean (s.d.^b^)                          65.34 (11.49)   62.88 (13.21)   64.20 (12.38)
   Range                                   22.87--95.69    22.43--96.29    22.43--96.29

VHM&PP=Vorarlberg Health Monitoring and Promotion Program; BMI=body mass index.

Eligible participants were enrolled between 1985 and 2001, had complete baseline data for BMI, smoking and occupational group, and had no history of malignant cancer prior to or within 1 year after baseline. Participants with nonmelanoma skin cancer were excluded.

s.d.: standard deviation.

BMI: body mass index (kg m^−2^) based on height and weight measured at baseline physical examination.

Occupational group classified according to insurance number for occupation at baseline, prior occupation (for pensioners) or husband\'s occupation (for housewives).

###### 

Estimated HR and 95% CI for incident cancers diagnosed among male participants in the VHM&PP Study Cohort 1985--2001, according to BMI at enrolment

                                                 **BMI (kg m^−2^)^a^**                                                                 
  --------------------------------------------- ----------------------- ------------------- ---------------------- ------------------- -------
  *All cancers*                                                                                                                        
   Incident cases/py^b^                               1364/10 293           1591/12 078            342/2459              40/259         
   HR (95% CI)^c^                                        1.00            0.97 (0.91--1.05)    0.96 (0.85--1.08)     0.94 (0.69--1.29)  0.37
                                                                                                                                        
  *Stomach cancer (ICD-9 151)*                                                                                                         
   Incident cases/py^b^                                 58/400                75/546                13/67                               
   HR (95% CI)^c^                                        1.00            1.04 (0.73--1.47)   0.72^a^ (0.40--1.33)                      0.44
                                                                                                                                        
  *Colon cancer (ICD-9 153)*                                                                                                           
   Incident cases/py^b^                                 86/663                128/942               39/275                7/44          
   HR (95% CI)^c^                                        1.00            1.14 (0.86--1.50)    1.56 (1.06--2.30)     2.48 (1.15--5.39)  0.005
                                                                                                                                        
  *Rectal cancer (ICD-9 154)*                                                                                                          
   Incident cases/py^b^                                 45/327                69/499                24/163                              
   HR (95% CI)^c^                                        1.00            1.20 (0.82--1.75)   1.66^a^ (1.01--2.73)                      0.053
                                                                                                                                        
  *Liver cancer (ICD-9 155)*                                                                                                           
   Incident cases/py^b^                                 18/128                29/197                10/92                               
   HR (95% CI)^c^                                        1.00            1.32 (0.73--2.37)   1.67^a^ (0.75--3.72)                      0.19
                                                                                                                                        
  *Pancreatic cancer (ICD-9 157)*                                                                                                      
   Incident cases/p^b^                                  19/129                31/250                14/109                              
   HR (95% CI)^c^                                        1.00            1.29 (0.73--2.27)   2.34^a^ (1.17--4.66)                      0.02
                                                                                                                                        
  *Lung cancer (ICD-9 162)*                                                                                                            
   Incident cases/py^b^                                209/1427              198/1288               50/308                7/32          
   HR (95% CI)^c^                                        1.00            0.80 (0.66--0.97)    0.88 (0.65--1.20)     0.88 (0.41--1.86)  0.15
                                                                                                                                        
  *Melanoma (ICD-9 172)*                                                                                                               
   Incident cases/py^b^                                 59/373                56/409                 7/48                               
   HR (95% CI)^c^                                        1.00            1.00 (0.68--1.46)   0.59^a^ (0.27--1.31)                      0.32
                                                                                                                                        
  *Prostate cancer (ICD-9 185)*                                                                                                        
   Incident cases                                      446/4001              583/5165               99/766                10/88         
   HR (95% CI)^c^                                        1.00            1.03 (0.91--1.17)    0.82 (0.66--1.03)     0.73 (0.39--1.37)  0.16
                                                                                                                                        
  *Bladder cancer (ICD-9 188)*                                                                                                         
   Incident cases/py^b^                                 78/522                78/507                19/136                              
   HR (95% CI)^c^                                        1.00            0.81 (0.59--1.11)   0.74^a^ (0.45--1.22)                      0.15
                                                                                                                                        
  *Kidney cancer (ICD-9 189)*                                                                                                          
   Incident cases/py^b^                                 46/356                70/486                21/162                              
   HR (95% CI)^c^                                        1.00            1.19 (0.82--1.74)   1.46^a^ (0.87--2.46)                      0.14
                                                                                                                                        
  *Non-Hodgkin\'s lymphoma (ICD-9 200*+*202)*                                                                                          
   Incident cases/py^b^                                 31/236                45/288                 8/54                               
   HR (95% CI)^c^                                        1.00            1.26 (0.80--2.01)   0.91^a^ (0.41--1.99)                      0.86

VHM&PP=Vorarlberg Health Monitoring and Promotion Program; HR=hazards ratio; CI=confidence interval; ICD=International Classification of Diseases; BMI=body mass index.

Obese categories (class I and class II and III) were combined as needed to ensure at least five cases in each.

Person-years.

The Cox proportional-hazards model was stratified according to age at enrolment (in years) and adjusted for smoking status and occupational group.

###### 

Estimated HR and 95% CI for incident cancers diagnosed among female participants in the VHM&PP Study Cohort 1985--2001, according to BMI at enrolment

                                                **BMI (kg m^−2^)^a^**                                                                 
  -------------------------------------------- ----------------------- ------------------- ---------------------- ------------------- ---------
  *All cancers*                                                                                                                       
   Incident cases/py^b^                              1425/10 712            997/6883              369/2493              113/795            
   HR (95% CI)^c^                                       1.00            1.05 (0.96--1.14)    1.16 (1.03--1.30)     1.18 (0.97--1.43)    0.008
                                                                                                                                           
  *Stomach cancer (ICD-9 151)*                                                                                                        
   Incident cases/py^b^                                56/394                36/212                20/146                6/45              
   HR (95% CI)^c^                                       1.00            0.78 (0.51--1.20)    1.28 (0.76--2.15)     1.34 (0.57--3.13)    0.48
                                                                                                                                           
  *Colon cancer (ICD-9 153)*                                                                                                          
   Incident cases/py^b^                                122/958               106/773               35/238                8/82              
   HR (95% CI)^c^                                       1.00            1.13 (0.86--1.47)    1.11 (0.76--1.62)     0.88 (0.43--1.81)    0.73
                                                                                                                                           
  *Rectal cancer (ICD-9 154)*                                                                                                         
   Incident cases/py^b^                                68/504                48/315                12/100                5/27              
   HR (95% CI)^c^                                       1.00            0.90 (0.62--1.31)    0.66 (0.36--1.23)     0.96 (0.38--2.39)    0.32
                                                                                                                                           
  *Pancreatic cancer (ICD-9 157)*                                                                                                     
   Incident cases/py^b^                                29/231                21/154                15/80                                   
   HR (95% CI)^c^                                       1.00            0.87 (0.49--1.53)   1.42^a^ (0.76--2.68)                         0.4
                                                                                                                                           
  *Lung cancer (ICD-9 162)*                                                                                                           
   Incident cases/py^b^                                64/513                45/300                17/97                                   
   HR (95% CI)^c^                                       1.00            1.00 (0.68--1.48)   0.87^a^ (0.50--1.50)                        0.67
                                                                                                                                           
  *Melanoma (ICD-9 172)*                                                                                                              
   Incident cases/py^b^                                79/535                38/268                13/77                                   
   HR (95% CI)^c^                                       1.00            1.03 (0.68--1.54)   0.86^a^ (0.47--1.57)                        0.72
                                                                                                                                           
  *Breast cancer (ICD-9 174)*                                                                                                         
   Incident cases/py^b^                               551/4162              335/2326              123/860               36/270             
   HR (95% CI)^c^                                       1.00            0.96 (0.83--1.10)    1.07 (0.88--1.31)     1.01 (0.72--1.42)     0.8
                                                                                                                                           
  *Cervical cancer (ICD-9 180)*                                                                                                       
   Incident cases/py^b^                                41/205                17/106                 6/43                                   
   HR (95% CI)^c^                                       1.00            0.85 (0.47--1.54)   0.69^a^ (0.29--1.66)                        0.37
                                                                                                                                           
  *Cancer of the uterine corpus (ICD-9 182)*                                                                                          
   Incident cases/py^b^                                63/452                59/441                33/230                20/93             
   HR (95% CI)^c^                                       1.00            1.29 (0.90--1.86)    2.13 (1.38--3.27)     3.93 (2.35--6.56)   \<0.001
                                                                                                                                           
  *Ovarian cancer (ICD-9 183)*                                                                                                        
   Incident cases/py^b^                                61/490                39/245                21/141                                  
   HR (95% CI)^c^                                       1.00            1.03 (0.68--1.56)   1.25^a^ (0.75--2.08)                        0.44
                                                                                                                                           
  *Bladder cancer (ICD-9 188)*                                                                                                        
   Incident cases/py^b^                                21/128                22/120                11/85                                   
   HR (95% CI)^c^                                       1.00            1.35 (0.74--2.48)   1.60^a^ (0.76--3.36)                        0.19
                                                                                                                                           
  *Kidney cancer (ICD-9 189)*                                                                                                         
   Incident cases/py^b^                                32/290                44/299                12/77                                   
   HR (95% CI)^c^                                       1.00            1.81 (1.13--2.89)   1.14^a^ (0.58--2.24)                         0.3
                                                                                                                                           
  *Thyroid cancer (ICD-9 193)*                                                                                                        
   Incident cases/py^b^                                29/173                24/183                 8/52                                   
   HR (95% CI)^c^                                       1.00            1.45 (0.82--2.58)   1.18^a^ (0.53--2.65)                        0.44
                                                                                                                                           
  *Non-Hodgkin\'s lymphoma (ICD-9 200*+202)                                                                                           
   Incident cases/py^b^                                22/154                24/170                18/126                                  
   HR (95% CI)^c^                                       1.00            1.64 (0.89--3.01)   2.86^a^ (1.49--5.49)                        0.002

VHM&PP=Vorarlberg Health Monitoring and Promotion Program; HR=hazards ratio; CI=confidence interval; ICD=International Classification of Diseases; BMI=body mass index.

Obese categories (class I and class II and III) were combined as needed to ensure at least five cases in each.

Person-years.

The Cox proportional-hazards model was stratified according to age at enrolment (in years) and adjusted for smoking status and occupational group.
